share_log

Stephens & Co. Initiates Coverage On Catalyst Pharmaceuticals With Overweight Rating, Announces Price Target of $35

Benzinga ·  Nov 18, 2024 10:28  · Ratings

Stephens & Co. analyst Sudan Loganathan initiates coverage on Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Overweight rating and announces Price Target of $35.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment